Virax Biolabs shares surge 12.23% intraday after announcing $5 million private placement closing.

Virax Biolabs Group surged 12.23% intraday after announcing the completion of a $5 million private placement, signaling improved liquidity and investor confidence. The firm also reported constructive FDA feedback on its ViraxImmune™ study evaluating T cell dysfunction in post-acute infection syndromes, alongside progress in UK clinical recruitment. These developments, combined with strategic partnerships like the Emory University collaboration and an upcoming FDA pre-submission meeting, reinforced optimism about the company’s pipeline and regulatory pathway. The recent funding and clinical advancements align with the stock’s sharp intraday rally, highlighting key catalysts for its biotech-focused operations.